Identification

Name
Levocetirizine
Accession Number
DB06282
Type
Small Molecule
Groups
Approved
Description

Levocetirizine is a third-generation non-sedative antihistamine indicated for the relief of symptoms associated with seasonal and perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It was developed from the second-generation antihistamine cetirizine. Levocetirizine is the R-enantiomer of the cetirizine racemate. Levocetirizine is an inverse agonist that decreases activity at histamine H1 receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hay fever. It does not prevent the actual release of histamine from mast cells. Levocetirizine was approved by the United States Food and Drug Administration on May 25, 2007 and is marketed under the brand XYZAL® by sanofi-aventis U.S. LLC.

Structure
Thumb
Synonyms
  • 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
Product Ingredients
IngredientUNIICASInChI Key
Levocetirizine dihydrochlorideSOD6A38AGA130018-87-0PGLIUCLTXOYQMV-GHVWMZMZSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levocetirizine DihydrochlorideSolution.5 mg/mLOralWinthrop U.S.2008-04-02Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralWinthrop U.S.2007-08-09Not applicableUs
XyzalTablet5 mg/1OralUCB Farchim S.A.2008-02-192016-04-05Us
XyzalTablet, film coated5 mg/1OralUcb Inc2007-08-09Not applicableUs50474 0920 90 nlmimage10 0a47850c
XyzalSolution.5 mg/mLOralPhysicians Total Care, Inc.2010-04-27Not applicableUs
XyzalSolution.5 mg/mLOralSanofi Aventis2008-04-02Not applicableUs
XyzalTablet, film coated5 mg/1OralSanofi Aventis2007-08-09Not applicableUs00024 5800 90 nlmimage10 4112a085
XyzalTablet5 mg/1OralPhysicians Total Care, Inc.2007-11-06Not applicableUs
XyzalSolution.5 mg/mLOralUcb Inc2008-04-022018-06-08Us
XyzalTablet, film coated5 mg/1OralSanofi Aventis2017-07-24Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Levocetirizine DihydrochlorideTablet5 mg/1OralCamber Pharmaceuticals2012-06-29Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralYiling Pharmaceutical, Inc.2017-03-29Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralApotex Corporation2015-02-13Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1Oralbryant ranch prepack2012-06-29Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralDispensing Solutions, Inc.2011-09-06Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2015-02-13Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1Oralbryant ranch prepack2011-02-25Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1OralCarlsbad Technology, Inc.2015-11-11Not applicableUs
Levocetirizine DihydrochlorideTablet, film coated5 mg/1Oralbryant ranch prepack2016-01-11Not applicableUs
Levocetirizine DihydrochlorideTablet5 mg/1OralNostrum Laboratories, Inc.2016-12-202017-12-22Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24HR Allergy ReliefTablet, coated5 mg/1OralCardinal Health2018-03-12Not applicableUs
Allergy ReliefTablet, coated5 mg/1OralAlbertsons Companies2018-06-30Not applicableUs
Allergy ReliefTablet, coated5 mg/1OralAmerisource Bergen Drug Corportaion2018-04-20Not applicableUs
Childrens Xyzal AllergySolution.5 mg/mLOralChattem, Inc.2017-02-16Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralRugby2018-04-20Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralWalgreens2018-03-26Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralDr Reddy's Laboratories2018-03-12Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralWalgreens2018-03-12Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralDr Reddy's Laboratories2018-03-12Not applicableUs
Levocetirizine DihydrochlorideTablet, coated5 mg/1OralCVS Health2018-04-15Not applicableUs
International/Other Brands
Xusal
Categories
UNII
6U5EA9RT2O
CAS number
130018-77-8
Weight
Average: 388.89
Monoisotopic: 388.1553704
Chemical Formula
C21H25ClN2O3
InChI Key
ZKLPARSLTMPFCP-OAQYLSRUSA-N
InChI
InChI=1S/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/t21-/m1/s1
IUPAC Name
2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
SMILES
OC(=O)COCCN1CCN(CC1)[C@H](C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). This increased affinity has unknown clinical relevance.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
inhibitor
Human
Absorption

Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, peak plasma concentrations are achieved 0.9 hour after administration of the oral tablet. The accumulation ratio following daily oral administration is 1.12 with steady state achieved after 2 days. Peak concentrations are typically 270 ng/mL and 308 ng/mL following a single and a repeated 5 mg once daily dose, respectively. Food had no effect on the extent of exposure (AUC) of the levocetirizine tablet, but Tmax was delayed by about 1.25 hours and Cmax was decreased by about 36% after administration with a high fat meal; therefore, levocetirizine can be administered with or without food.

Volume of distribution

Approximately 0.4 L/kg.

Protein binding

91-92%.

Metabolism

Levocetirizine is poorly metabolized and mostly excreted. This is favourable as it is unlikely to be modified by drugs administered concomitantly.

Route of elimination

Renal excretion, mainly tubular excretion - therefore dose adjustment may be required in patients with renal impairment. After admininstration of a 5 mg dose of radiolabeled oral levocetirizine - 85.4% was excreted in urine and and 12.9% in feces (146 hours later).

Half life

8-9 hours.

Clearance

about 0.63 mL/kg/min (oral total body clearance).

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Levocetirizine H1-Antihistamine ActionDrug action
Levocetirizine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Levocetirizine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Levocetirizine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Levocetirizine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Levocetirizine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Levocetirizine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Levocetirizine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Levocetirizine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Levocetirizine.Approved, Illicit, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Levocetirizine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Levocetirizine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Levocetirizine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Levocetirizine.Approved, Illicit, Investigational
ApalutamideThe serum concentration of Levocetirizine can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Levocetirizine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Levocetirizine.Approved
AtazanavirThe metabolism of Levocetirizine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Levocetirizine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Azaperone.Investigational, Vet Approved
AzelastineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Levocetirizine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Benperidol.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Levocetirizine.Approved
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Levocetirizine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineLevocetirizine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Levocetirizine.Approved, Investigational
BoceprevirThe metabolism of Levocetirizine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Levocetirizine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Levocetirizine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Levocetirizine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Levocetirizine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Bupivacaine.Approved, Investigational
BuprenorphineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Levocetirizine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Levocetirizine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Levocetirizine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levocetirizine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Levocetirizine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Levocetirizine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Levocetirizine.Approved
CeritinibThe serum concentration of Levocetirizine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Levocetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Levocetirizine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Levocetirizine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Levocetirizine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Levocetirizine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Levocetirizine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Levocetirizine.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Levocetirizine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Levocetirizine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Levocetirizine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Levocetirizine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Levocetirizine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Levocetirizine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Levocetirizine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Levocetirizine.Approved
CobicistatThe metabolism of Levocetirizine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Levocetirizine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Levocetirizine.Approved, Investigational
CrizotinibThe metabolism of Levocetirizine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Levocetirizine can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Levocetirizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Levocetirizine.Approved
DabrafenibThe serum concentration of Levocetirizine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocetirizine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Levocetirizine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Levocetirizine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Levocetirizine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Levocetirizine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Levocetirizine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Levocetirizine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Levocetirizine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Levocetirizine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Levocetirizine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Levocetirizine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Levocetirizine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative and stimulatory activities of Levocetirizine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Levocetirizine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Levocetirizine.Approved, Illicit
DihydroergotamineThe metabolism of Levocetirizine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Levocetirizine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Levocetirizine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Levocetirizine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Doramectin.Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dotarizine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Levocetirizine.Approved, Investigational
DoxycyclineThe metabolism of Levocetirizine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Levocetirizine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved, Illicit
DronedaroneThe metabolism of Levocetirizine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levocetirizine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Levocetirizine.Approved, Investigational
EnzalutamideThe serum concentration of Levocetirizine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Eperisone.Approved, Investigational
ErythromycinThe metabolism of Levocetirizine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Levocetirizine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Levocetirizine.Approved, Investigational
EthanolLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Levocetirizine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Levocetirizine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Levocetirizine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Levocetirizine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Levocetirizine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Levocetirizine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Levocetirizine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Levocetirizine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Levocetirizine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Levocetirizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Levocetirizine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levocetirizine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Levocetirizine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levocetirizine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Levocetirizine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Levocetirizine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Levocetirizine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Levocetirizine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Levocetirizine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Levocetirizine.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Levocetirizine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Levocetirizine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocetirizine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Levocetirizine.Approved, Investigational
HydrocodoneLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Levocetirizine.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Levocetirizine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocetirizine.Approved, Investigational
IdelalisibThe metabolism of Levocetirizine can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocetirizine.Approved
ImatinibThe metabolism of Levocetirizine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocetirizine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Levocetirizine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Levocetirizine.Approved
IsavuconazoleThe serum concentration of Levocetirizine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Levocetirizine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Levocetirizine.Approved, Vet Approved
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Levocetirizine.Approved, Investigational
ItraconazoleThe metabolism of Levocetirizine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Levocetirizine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocetirizine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Levocetirizine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Levocetirizine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Levocetirizine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levocabastine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Levocetirizine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Levocetirizine.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Levocetirizine.Approved, Investigational
Lithium cationThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Levocetirizine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Levocetirizine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Levocetirizine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Levocetirizine can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Levocetirizine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levocetirizine.Approved
LuliconazoleThe serum concentration of Levocetirizine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Levocetirizine can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Levocetirizine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocetirizine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Levocetirizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Levocetirizine.Investigational
MephentermineMephentermine may decrease the sedative activities of Levocetirizine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Meptazinol.Experimental
MepyramineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Mepyramine.Approved, Vet Approved
MesoridazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocetirizine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Levocetirizine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Levocetirizine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocetirizine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Levocetirizine.Approved
MethotrimeprazineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Levocetirizine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levocetirizine.Approved, Investigational
MibefradilThe metabolism of Levocetirizine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Levocetirizine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Levocetirizine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Levocetirizine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved, Investigational
MirtazapineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Levocetirizine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may decrease the sedative activities of Levocetirizine.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Levocetirizine.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Levocetirizine.Approved
NefazodoneThe metabolism of Levocetirizine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Levocetirizine can be decreased when combined with Nelfinavir.Approved
NeomycinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Neomycin.Approved, Vet Approved
NetupitantThe serum concentration of Levocetirizine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Levocetirizine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Levocetirizine can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibThe metabolism of Levocetirizine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Levocetirizine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Levocetirizine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Levocetirizine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Levocetirizine.Approved, Investigational
OlaparibThe metabolism of Levocetirizine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Levocetirizine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Opium.Approved, Illicit
OrphenadrineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Levocetirizine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levocetirizine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Levocetirizine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Levocetirizine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Levocetirizine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Levocetirizine.Approved
ParaldehydeLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Levocetirizine.Approved, Vet Approved
PentobarbitalThe metabolism of Levocetirizine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
PerazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Levocetirizine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Levocetirizine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Phenibut.Experimental
PheniramineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Pheniramine.Approved
PhenobarbitalThe metabolism of Levocetirizine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Levocetirizine.Approved, Illicit
PhenytoinThe metabolism of Levocetirizine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Levocetirizine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Levocetirizine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Levocetirizine can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Levocetirizine.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Levocetirizine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleLevocetirizine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Levocetirizine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Levocetirizine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocetirizine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levocetirizine.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Levocetirizine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Levocetirizine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative and stimulatory activities of Levocetirizine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pyrantel.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levocetirizine.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levocetirizine.Approved, Investigational
RanolazineThe metabolism of Levocetirizine can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocetirizine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Levocetirizine.Approved, Investigational
RifabutinThe metabolism of Levocetirizine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Levocetirizine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Levocetirizine can be increased when combined with Rifapentine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocetirizine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Levocetirizine.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Rizatriptan.Approved
RomifidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Romifidine.Vet Approved
RopiniroleLevocetirizine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ropivacaine.Approved
RotigotineLevocetirizine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Levocetirizine can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Levocetirizine.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levocetirizine.Approved, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levocetirizine.Approved
SaquinavirThe metabolism of Levocetirizine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Levocetirizine can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Levocetirizine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocetirizine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levocetirizine.Approved, Vet Approved
SildenafilThe metabolism of Levocetirizine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Levocetirizine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Levocetirizine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
St. John's WortThe serum concentration of Levocetirizine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Levocetirizine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.Approved, Investigational
SulfisoxazoleThe metabolism of Levocetirizine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sumatriptan.Approved, Investigational
SuvorexantLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tasimelteon.Approved, Investigational
TelaprevirThe metabolism of Levocetirizine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Levocetirizine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Levocetirizine.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Terodiline.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Levocetirizine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetracaine.Approved, Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tetrodotoxin.Investigational
ThalidomideLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Levocetirizine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Levocetirizine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Levocetirizine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Levocetirizine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Levocetirizine.Approved, Investigational
TocilizumabThe serum concentration of Levocetirizine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Levocetirizine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Levocetirizine.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocetirizine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Levocetirizine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Levocetirizine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Levocetirizine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Levocetirizine.Approved
Valproic AcidThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Valproic Acid.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Levocetirizine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Veralipride.Experimental
VerapamilThe metabolism of Levocetirizine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Levocetirizine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Levocetirizine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levocetirizine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Levocetirizine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zolmitriptan.Approved, Investigational
ZolpidemLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levocetirizine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Levocetirizine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Levocetirizine.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Grant JA, Riethuisen JM, Moulaert B, DeVos C: A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002 Feb;88(2):190-7. [PubMed:11868924]
  2. Ferrer M: Pharmacokinetic evaluation of levocetirizine. Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):1035-47. doi: 10.1517/17425255.2011.590131. Epub 2011 Jun 4. [PubMed:21639816]
  3. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]
External Links
Human Metabolome Database
HMDB0240226
KEGG Drug
D07402
PubChem Compound
1549000
PubChem Substance
310264866
ChemSpider
1266001
BindingDB
85030
ChEBI
94559
ChEMBL
CHEMBL1201191
HET
LCR
Drugs.com
Drugs.com Drug Page
Wikipedia
Levocetirizine
ATC Codes
R06AE09 — Levocetirizine
PDB Entries
5dqf
FDA label
Download (167 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionSkin Inflammation1
1CompletedTreatmentAllergic Rhinitis (AR)1
1CompletedTreatmentAllergies1
1CompletedTreatmentFasting1
1CompletedTreatmentFasting State1
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentRhinitis1
2CompletedNot AvailableAllergic Rhinitis (AR)1
2CompletedTreatmentAllergic / Rhinitis / Rhinitis, Allergic, Seasonal / Seasonal1
2CompletedTreatmentCoughing1
2CompletedTreatmentNeoplasms, Colorectal1
3CompletedNot AvailableAtopic Dermatitis (AD)1
3CompletedTreatmentAllergic Rhinitis (AR)2
3CompletedTreatmentAllergic Rhinitis (AR) / Chronic Urticaria2
3CompletedTreatmentAllergic / Perennial / Rhinitis1
3CompletedTreatmentAllergic / Rhinitis / Seasonal1
3CompletedTreatmentDermatitis, Eczematous / Skin Inflammation1
3CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
3CompletedTreatmentRhinitis1
3CompletedTreatmentRhinitis, Allergic, Seasonal2
3CompletedTreatmentUrticarias2
3CompletedTreatmentVasomotor Rhinitis1
3Not Yet RecruitingTreatmentAngiœdema / Urticarias1
3TerminatedTreatmentAsthma Bronchial1
4CompletedNot AvailableAnti-allergic Agents1
4CompletedNot AvailableRhinitis, Allergic, Perennial2
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedTreatmentAllergic Rhinitis (AR)5
4CompletedTreatmentAllergic / Perennial / Rhinitis1
4CompletedTreatmentAtopic Dermatitis (AD) / Pruritus1
4CompletedTreatmentChronic Idiopathic Urticaria1
4CompletedTreatmentChronic Urticaria1
4CompletedTreatmentHypersensitivity1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
4CompletedTreatmentRhinitis, Allergic, Seasonal2
4CompletedTreatmentSeasonal Allergic Rhinitis (SAR)2
4Unknown StatusTreatmentChronic Idiopathic Urticaria / Urticarias1
4Unknown StatusTreatmentPerennial Allergic Rhinitis (PAR)1
Not AvailableCompletedNot AvailableRhinitis, Allergic, Perennial and Seasonal1
Not AvailableCompletedTreatmentRhinitis, Allergic, Seasonal1
Not AvailableTerminatedNot AvailableRhinitis / Urticarias1
Not AvailableUnknown StatusDiagnosticAsthma Bronchial / Asthma, Allergic / Non-allergic Asthma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, coatedOral5 mg/1
Tablet, film coatedOral5 mg/1
SolutionOral.5 mg/mL
TabletOral5 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5698558No1993-03-242013-03-24Us
US8633194No2007-10-162027-10-16Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0658 mg/mLALOGPS
logP2.98ALOGPS
logP0.87ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.59ChemAxon
pKa (Strongest Basic)7.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.01 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity106.87 m3·mol-1ChemAxon
Polarizability41.93 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0019000000-e24b60aef9a19aa0ca89
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0090000000-4fbbabe7bf3d0ad4cab5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0190000000-8783499dc5c2d31a3f7a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0uxr-0790000000-4efaf73700a535eb98e9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0920000000-f952b59e46cde6d2cfac
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0492000000-90537be4971a327c0fb1

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Diphenylmethane / Chlorobenzene / Halobenzene / N-alkylpiperazine / Aralkylamine / Aryl halide / 1,4-diazinane / Aryl chloride / Piperazine / Amino acid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Ferrer M: Pharmacokinetic evaluation of levocetirizine. Expert Opin Drug Metab Toxicol. 2011 Aug;7(8):1035-47. doi: 10.1517/17425255.2011.590131. Epub 2011 Jun 4. [PubMed:21639816]
  2. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. [PubMed:18336052]

Drug created on March 19, 2008 10:21 / Updated on August 02, 2018 07:52